Cas Stefaan Dejonckheere , Lara Caglayan , Andrea Renate Glasmacher , Shari Wiegreffe , Julian Philipp Layer , Younèss Nour , Davide Scafa , Gustavo Renato Sarria , Simon Spohn , Markus Essler , Stefan Hauser , Manuel Ritter , Marit Bernhardt , Glen Kristiansen , Anca-Ligia Grosu , Constantinos Zamboglou , Eleni Gkika
{"title":"局部前列腺癌立体定向体放射治疗后的前列腺特异性抗原动力学:范围综述和荟萃分析。","authors":"Cas Stefaan Dejonckheere , Lara Caglayan , Andrea Renate Glasmacher , Shari Wiegreffe , Julian Philipp Layer , Younèss Nour , Davide Scafa , Gustavo Renato Sarria , Simon Spohn , Markus Essler , Stefan Hauser , Manuel Ritter , Marit Bernhardt , Glen Kristiansen , Anca-Ligia Grosu , Constantinos Zamboglou , Eleni Gkika","doi":"10.1016/j.radonc.2024.110642","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.</div></div><div><h3>Methods</h3><div>A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.</div></div><div><h3>Results</h3><div>Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (<em>r</em> = − 0.59; <em>p</em> < 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (<em>r</em> = −0.49; <em>p</em> = 0.046).</div></div><div><h3>Conclusion</h3><div>PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"202 ","pages":"Article 110642"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis\",\"authors\":\"Cas Stefaan Dejonckheere , Lara Caglayan , Andrea Renate Glasmacher , Shari Wiegreffe , Julian Philipp Layer , Younèss Nour , Davide Scafa , Gustavo Renato Sarria , Simon Spohn , Markus Essler , Stefan Hauser , Manuel Ritter , Marit Bernhardt , Glen Kristiansen , Anca-Ligia Grosu , Constantinos Zamboglou , Eleni Gkika\",\"doi\":\"10.1016/j.radonc.2024.110642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.</div></div><div><h3>Methods</h3><div>A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.</div></div><div><h3>Results</h3><div>Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (<em>r</em> = − 0.59; <em>p</em> < 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (<em>r</em> = −0.49; <em>p</em> = 0.046).</div></div><div><h3>Conclusion</h3><div>PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.</div></div>\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\"202 \",\"pages\":\"Article 110642\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0167814024043044\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167814024043044","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis
Purpose
Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.
Methods
A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.
Results
Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (r = − 0.59; p < 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (r = −0.49; p = 0.046).
Conclusion
PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.
期刊介绍:
Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.